Physician profile
Stephen Edwin Wilson
NPI 1760430953
$28,143.38
in general payments reported to CMS, 2019-2025
43 companies · $1,938 in 2025
The $1,938 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,267 · 2020: $2,368 · 2021: $4,126 · 2022: $5,385 · 2023: $3,566 · 2024: $2,493 · 2025: $1,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,996.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $9,242.52 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $2,843.05 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $2,105.14 | 2019-2024 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,810.77 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $1,340.19 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $1,323.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,320.10 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $1,279.30 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $909.16 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $530.05 | 2019-2023 | Gardasil 9, Vaxneuvance, Belsomra |
| Sanofi-Aventis U.S. LLC | $507.62 | 2019-2025 | |
| Amgen INC. | $488.78 | 2019-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $474.60 | 2019-2025 | |
| Esperion Therapeutics, INC. | $461.33 | 2020-2023 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $412.40 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.